Is Your Antifungal Cream Working? Microemulsions Might Be the Answer
"Discover how microemulsion-based gels could revolutionize the treatment of fungal skin infections, offering better drug delivery and fewer side effects compared to conventional creams."
Fungal infections of the skin, hair, and nails—dermatophytoses—are frustratingly common. These infections, caused by fungi like Microsporum and Trichophyton, lead to uncomfortable symptoms such as itching, scaling, and redness. While rarely life-threatening, these infections can significantly diminish one's quality of life and often recur, making effective treatment a persistent challenge.
Clotrimazole (CTZ) is a widely used antifungal medication that inhibits ergosterol synthesis, disrupting fungal cell integrity. Topical application is favored to avoid systemic side effects. However, the skin's stratum corneum acts as a formidable barrier, limiting drug penetration and efficacy. Therefore, innovative formulations are needed to enhance drug delivery to the site of infection.
Microemulsions (MEs) have emerged as a promising drug delivery system for topical applications. These mixtures of oil, water, and surfactants spontaneously form stable, clear liquids with nanometer-sized droplets. MEs enhance drug solubility, and their components can boost skin penetration. By incorporating a gelling agent, microemulsion-based gels (MBGs) can be created to improve viscosity and skin adherence, offering a superior method for delivering antifungal agents.
Resistance and Prescribing Concerns
The CDC report says antimicrobial-resistant dermatophytosis has been identified in at least 11 U.S. states, with patients experiencing extensive lesions and delays in diagnosis. It notes that overuse and misuse of topical antifungals, particularly antifungal-corticosteroid combination creams, likely exacerbate the emergence and spread of resistance. Treatment may be topical, systemic, or a combination, depending on the infection’s extent, severity, site, and causative organism. A market report estimates the global dermatophytosis treatment market at $7.8 billion in 2025 and projects $12.4 billion by 2034, with antifungal creams holding a 38.5% share.
From Ancient Descriptions to Sabouraud
Descriptions of dermatophytosis-like lesions date back to the Roman era. The historical account on Wikidoc says Raimond Sabouraud advanced dermatomycology around 1890 through studies of dermatophyte taxonomy, morphology, and treatment. It reports that he classified these fungi into four genera, three of which remain in use by mycologists. A 2010 historical review notes that topical treatments, including Whitfield ointment, were known in the 19th century, while ketoconazole was introduced in 1981 as the first azole derivative with systemic action.
Microemulsions vs. Conventional Creams: A New Era in Antifungal Treatment?
A recent study published in Skin Pharmacology and Physiology explores the potential of clotrimazole microemulsions (CTZ-ME) and microemulsion-based gels (CTZ-MBG) in treating dermatophytosis. Researchers compared these formulations to a conventional CTZ cream, focusing on antifungal activity, skin permeation, and retention. The goal was to determine if MEs and MBGs could improve drug delivery and efficacy compared to traditional creams.
- Formulation: CTZ-ME and CTZ-MBG were prepared with 1% w/w clotrimazole.
- Antifungal Activity: The agar diffusion method was used to assess antifungal activity against T. mentagrophytes.
- Skin Penetration: Pig skin was used in in vitro penetration studies with modified Franz diffusion cells.
- Analysis: HPLC was used to measure drug amounts in the receptor fluid, skin membrane, and donor compartment.
Formulation and Measurement Studies
A study titled “Factorial Design Executed Development of Miconazole Nitrate Microemulsion Based Bioadhesive Gel and Its Evaluation” reports that its experimentation was carried out in triplicate. A clotrimazole ufosome paper notes that similar results had been reported for clotrimazole microemulsions, clotrimazole-loaded three-dimensionally structured hybrid vesicles, and roxithromycin ufosomes. Separately, a study validated a UPLC-MS/MS method to estimate resveratrol in rat skin from a liposphere gel formulation and applied it to rat dermatokinetic studies. These sources describe formulation and measurement research, not evidence that microemulsions improve clinical outcomes in people.
Evidence Remains Uncertain
The Cochrane review rates the overall quality of evidence for the assessed outcomes as low to very low. It concludes that there is currently insufficient evidence to decide whether any one treatment for fungal infections of the groin and body is better than the others. This uncertainty limits how confidently treatment comparisons can guide decisions. The review’s finding is about the evidence it assessed and does not establish that all treatments are equivalent.
Formulation and Drug Comparisons
In a dermal-delivery study, clotrimazole microemulsion gel formulations made with 1.0% (w/w) Carbopol 980 showed dermal clotrimazole concentrations comparable to the microemulsions and up to 2.4-fold higher than the commercial Lotrimin® clotrimazole cream. In a separate randomized, double-blind trial of tinea cruris and tinea corporis, 1% butenafine recipients had higher clinical cure at one week than 1% clotrimazole recipients (26.5% versus 2.9%). Mycological cure at that point was also higher with butenafine (61.7% versus 17.6%). The formulation comparison and the drug trial assess different questions, so the results should not be treated as a direct head-to-head comparison of microemulsion gel with butenafine.
The Future of Fungal Infection Treatment
Microemulsions and microemulsion-based gels hold considerable promise for improving the topical treatment of fungal infections. Their ability to enhance drug retention in the skin, coupled with effective antifungal activity, suggests a potential advantage over conventional creams. As research continues to refine these formulations, they may offer a more effective and targeted approach to managing dermatophytosis, reducing recurrence and improving patient outcomes. These findings highlight a significant step forward in dermatological treatments, potentially leading to more effective solutions for common and persistent fungal infections.
Delivery Choices and Recalcitrant Disease
Microemulsions are described as nanocarriers consisting of an oil phase, a surfactant, a co-surfactant, and an aqueous phase. Dermatophytes including T. rubrum, T. interdigitale, and T. mentagrophytes are identified as major causes of human skin and nail dermatophytosis. Treatment can involve topical or oral antifungals, and topical agents are used for several less severe forms of tinea. A 2025 review describes recalcitrant dermatophytosis as chronic infection with recurrences or relapses, sometimes presenting with unusual or severe manifestations.
Treatment Options and Their Limits
A review of novel topical antifungal agents says oral antifungals are the mainstay of dermatophytosis management, while noting limitations including antifungal drug resistance and potential adverse reactions. A 2024 case-study compilation describes combination regimens featuring sertaconazole, terbinafine, amorolfine, and adjunct therapies under the brand Zorbax across cases involving several fungal conditions, including chronic and recurrent dermatophytosis. A separate study reports findings on a combination of 30% salicylic acid peel and luliconazole 1% cream for superficial dermatophytosis. Another study notes that head-to-head comparative data on topical agents remain limited and evaluates amorolfine, luliconazole, sertaconazole, and terbinafine for tinea corporis and tinea cruris.